logo
ResearchBunny Logo
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial

Medicine and Health

Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial

K. Mautner, M. Gottschalk, et al.

Discover groundbreaking insights from a phase 2/3 randomized controlled trial that compares innovative cell therapies with corticosteroid injections for knee osteoarthritis, led by an expert team including Ken Mautner, Michael Gottschalk, and Scott D. Boden. This study reveals that, after one year, these advanced treatments did not outperform conventional corticosteroids in alleviating pain or enhancing function.

00:00
00:00
~3 min • Beginner • English
Abstract
Various types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections. Here we aimed to identify the safety and efficacy of cell injections from autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells, in comparison to corticosteroid injection (CSI). The study was a phase 2/3, four-arm parallel, multicenter, single-blind, randomized, controlled clinical trial with 480 patients with a diagnosis of knee osteoarthritis (Kellgren-Lawrence II-IV). Participants were randomized to the three different arms with a 3:1 distribution. Arm 1: autologous bone marrow aspirate concentrate (n=120), CSI (n = 40); arm 2: umbilical cord tissue-derived mesenchymal stromal cells (n=120), CSI (n = 40); arm 3: stromal vascular fraction (n = 120), CSI (n = 40). The co-primary endpoints were the visual analog scale pain score and Knee injury and Osteoarthritis Outcome Score pain score at 12 months versus baseline. Analyses of our primary endpoints, with 440 patients, revealed that at 1 year post injection, none of the three orthobiologic injections was superior to another, or to the CSI control. In addition, none of the four groups showed a significant change in magnetic resonance imaging osteoarthritis score compared to baseline. No procedure-related serious adverse events were reported during the study period. In summary, this study shows that at 1 year post injection, there was no superior orthobiologic as compared to CSI for knee osteoarthritis. ClinicalTrials.gov Identifier: NCT03818737
Publisher
Nature Medicine
Published On
Dec 29, 2023
Authors
Ken Mautner, Michael Gottschalk, Scott D. Boden, Alison Akard, Won C. Bae, Lora Black, Blake Boggess, Paramita Chatterjee, Christine B. Chung, Kirk A. Easley, Greg Gibson, Josh Hackel, Katie Jensen, Linda Kippner, Chad Kurtenbach, Joanne Kurtzberg, R. Amadeus Mason, Benjamin Noonan, Krishnendu Roy, Verle Valentine, Carolyn Yeago, Hicham Drissi
Tags
knee osteoarthritis
cell therapy
corticosteroid
pain reduction
function improvement
clinical trial
adverse events
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny